Rubitecan (CAS 91421-42-0)
See product citations (1)
QUICK LINKS
Rubitecan is a compound that has garnered attention in the field of cancer research due to its potential to interfere with the replication of DNA in rapidly dividing cells. It is a derivative of camptothecin, which is known for its topoisomerase I inhibitory activity, a critical enzyme in DNA replication. Studies involving Rubitecan focus on understanding its mechanism of action, specifically how it stabilizes the complex between topoisomerase I and DNA, leading to DNA damage and cell death. Research also delves into the compound′s ability to induce apoptosis in various cancer cell lines. Additionally, Rubitecan is used in the synthesis of analogs that may possess improved solubility or efficacy.
Rubitecan (CAS 91421-42-0) References
- A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. | Stehlin, JS., et al. 1999. Int J Oncol. 14: 821-31. PMID: 10200331
- Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). | Giovanella, BC., et al. 2002. Int J Oncol. 20: 81-8. PMID: 11743646
- Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts. | Sands, H., et al. 2002. Anticancer Drugs. 13: 965-75. PMID: 12394260
- Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. | Fracasso, PM., et al. 2002. Ann Oncol. 13: 1819-25. PMID: 12419757
- Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. | Schoemaker, NE., et al. 2002. Cancer Chemother Pharmacol. 50: 514-7. PMID: 12451480
- Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. | . 2004. Drugs R D. 5: 305-11. PMID: 15357630
- Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. | Kuppens, IE., et al. 2004. Clin Colorectal Cancer. 4: 163-80. PMID: 15377400
- Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. | Burris, HA., et al. 2005. Oncologist. 10: 183-90. PMID: 15793221
- Human multidrug resistance associated protein 4 confers resistance to camptothecins. | Tian, Q., et al. 2005. Pharm Res. 22: 1837-53. PMID: 16132345
- Alternative administration of camptothecin analogues. | Glaberman, U., et al. 2005. Expert Opin Drug Deliv. 2: 323-33. PMID: 16296757
- Phase II study of rubitecan in recurrent or metastatic head and neck cancer. | Caponigro, F., et al. 2008. Cancer Chemother Pharmacol. 62: 209-14. PMID: 17882418
- Recent advances in oral anticancer agents for colon cancer. | Shukla, RK. 2013. Future Oncol. 9: 1893-908. PMID: 24295419
- Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. | Hamilton, G., et al. 2014. Molecules. 19: 2077-88. PMID: 24549232
- PARP inhibition suppresses topoisomerase 1 poisoning induced Caspase-3 dependent cell death in zebrafish embryos. | Tsikarishvili, S., et al. 2021. Biochem Biophys Res Commun. 550: 166-170. PMID: 33706100
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rubitecan, 10 mg | sc-219998 | 10 mg | $88.00 |